Cargando…

C-Type natriuretic peptide: a potential urinary biomarker for renal remodeling and fibrosis during aging

Detalles Bibliográficos
Autores principales:	Sangaralingham, Jeson S, Heublein, Denise M, Grande, Joseph P, Cataliotti, Alessandro, Rule, Andrew D, McKie, Paul M, Martin, Fernando L, Burnett, John C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363257/ http://dx.doi.org/10.1186/1471-2210-11-S1-P60

Ejemplares similares

M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013)

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
por: McKie, Paul M., et al.
Publicado: (2014)

Pro-B-Type natriuretic peptide: a novel, specific biomarker for detection of left ventricular dysfunction in the general community
por: Macheret, Fima, et al.
Publicado: (2009)

C-type natriuretic peptide: the heart’s guardian angel
por: Sangaralingham, S Jeson, et al.
Publicado: (2020)

Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis
por: Martin, Fernando L, et al.
Publicado: (2011)

Chronic natriuretic peptide protein therapeutics
por: Chen, Horng H, et al.
Publicado: (2013)

Natriuretic peptide pathways in heart failure: further therapeutic possibilities
por: Sangaralingham, S Jeson, et al.
Publicado: (2022)

The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation
por: Schirger, John A, et al.
Publicado: (2009)

A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts
por: Ichiki, Tomoko, et al.
Publicado: (2009)

Progressive decline in circulating CNP with aging is associated with progressive cardiac fibrosis and myocardial impairment
por: Sangaralingham, Jeson, et al.
Publicado: (2009)

Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties
por: Chen, Horng H, et al.
Publicado: (2009)

The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011)

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up
por: Buglioni, Alessia, et al.
Publicado: (2015)

EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM
por: Ma, Xiao, et al.
Publicado: (2023)

A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction
por: Lim, Soo Ghim, et al.
Publicado: (2013)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
por: Martin, Fernando L., et al.
Publicado: (2012)

Arterial Remodeling in B-Type Natriuretic Peptide Knock-Out Females
por: Holditch, Sara J., et al.
Publicado: (2016)

B-type natriuretic peptide single nucleotide polymorphism rs198389 and survival in the general community
por: Boerrigter, Guido, et al.
Publicado: (2009)

Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling
por: Ichiki, Tomoko, et al.
Publicado: (2017)

MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
por: Burnett, John C, et al.
Publicado: (2015)

Atrial Natriuretic Peptide(31–67): A Novel Therapeutic Factor for Cardiovascular Diseases
por: da Silva, Gustavo Jose Justo, et al.
Publicado: (2021)

Weight Loss, Saline Loading, and the Natriuretic Peptide System
por: Arora, Pankaj, et al.
Publicado: (2015)

Innovative Therapeutics: Designer Natriuretic Peptides
por: Meems, Laura M.G., et al.
Publicado: (2016)

B-type natriuretic peptide single nucleotide polymorphism rs198389 is highly prevalent and impacts test characteristics of common assays
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2009)

Natriuretic Peptide Receptor 2 Locus Contributes to Carotid Remodeling
por: Korshunov, Vyacheslav A., et al.
Publicado: (2020)

Renal targeted protein therapeutics in experimental overt heart failure with renal dysfunction
por: Chen, Horng H, et al.
Publicado: (2009)

B-type natriuretic peptide for the prediction of left ventricular remodelling
por: Bauters, Christophe, et al.
Publicado: (2014)

Designer natriuretic peptides for heart failure: advanced in clinical development
por: Burnett, John
Publicado: (2011)

Impact of Aging on Urinary Natriuretic Peptides in Nocturia and Nocturnal Polyuria
por: Khosla, Lakshay, et al.
Publicado: (2022)

Modulating cGMP in heart failure by novel natriuretic peptides
por: Burnett, John C
Publicado: (2009)

The effect of saponins from Ampelozizyphus amazonicus Ducke on the renal Na(+) pumps’ activities and urinary excretion of natriuretic peptides
por: Diniz, Lúcio Ricardo Leite, et al.
Publicado: (2012)

Heads and Tails of Natriuretic Peptides: Neuroprotective Role of Brain Natriuretic Peptide
por: Fernández‐Susavila, Héctor, et al.
Publicado: (2017)

Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model
por: Ameenuddin, Syed, et al.
Publicado: (2011)

Enhancing natriuretic peptide bioactivity prevents bleomycin-induced pulmonary fibrosis
por: Baliga, Reshma S, et al.
Publicado: (2011)

Low voltage areas, atrial natriuretic peptides and fibrosis: Challenges and controversies
por: Floria, Mariana, et al.
Publicado: (2020)

Combination of brain natriuretic peptide and urinary albumin as a predictor of cardiovascular–renal events in outpatients with chronic kidney disease
por: Oyama, Shoya, et al.
Publicado: (2023)

Taipan Natriuretic Peptides Are Potent and Selective Agonists for the Natriuretic Peptide Receptor A
por: Vink, Simone, et al.
Publicado: (2023)

Novel roles of cardiac natriuretic peptides in renal compensatory hypertrophy
por: Schreiber, Andrea, et al.
Publicado: (2015)

C-type natriuretic peptide prevents angiotensin II-induced cardiac remodelling and dysfunction
por: Roloff, Konstanze, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_44vi8v7g68bqpmmjffutvc9npb